CoChat
Sign Up
Cited by 30Treatment of Major DepressionPsychotherapy Techniques and ApplicationsMental Health Treatment and Access

Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder

Brignone, Mélanie, Diamand, Françoise, Painchault, Caroline, Takyar, Shweta·2016·Current Medical Research and Opinion
DOI 10.1185/03007995.2015.1128404
Open this paper in CoChat — free account

Abstract

OBJECTIVES: To assess the relative efficacy and tolerability of vortioxetine against different antidepressant monotherapies in patients with major depressive disorder (MDD) with inadequate response to selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) therapy. METHODS: A systematic search was conducted for monotherapy studies in patients with MDD with inadequate response to first-line therapy. Treatments included SSRIs, SNRIs, and other antidepressants. Identified studies underwent a three-stage screening/data extraction process and critical appraisal. Adjusted indirect treatment comparisons (ITCs) on systematic literature review outputs were made using Bucher's method, comparing remission rates and withdrawal rates due to adverse events (AEs). RESULTS: Of 27 studies meeting the inclusion criteria, a few studies were of high quality according to the National Institute of Health and Care Excellence checklist. Three studies contributed to an evidence network for quantitative assessment comparing vortioxetine with agomelatine, sertraline, venlafaxine XR, and bupropion SR. Vortioxetine had a statistically significantly higher remission rate than agomelatine (risk difference [RD]: -11.0% [95% CI: -19.4; -2.6]), and numerically higher remission rates than sertraline (RD: -14.4% [95% CI: -29.9; 1.1]), venlafaxine (RD: -7.20% [95% CI: -24.3; 9.9]), and bupropion (RD: -10.70% [95% CI: -27.8; 6.4]). Withdrawal rates due to AEs were statistically significantly lower for vortioxetine than sertraline (RD: 12.1% [95% CI: 3.1; 21.1]), venlafaxine XR (RD: 12.3% [95% CI: 0.8; 23.8]), and bupropion SR (RD: 18.3% [95% CI: 6.4; 30.1]). CONCLUSIONS: The current systematic literature review found a few high quality switch studies assessing monotherapies in patients with MDD with inadequate response to SSRI/SNRIs. ITCs indicated that switching to vortioxetine leads to numerically higher remission rates compared with other antidepressants. Vortioxetine is a well tolerated treatment, showing statistically lower withdrawal rates due to AEs compared with other antidepressants. Vortioxetine is a relevant therapeutic alternative in patients experiencing inadequate response to prior SSRI or SNRI therapy.

Integrity signals

Registry

Crossref · 10.1185/03007995.2015.1128404

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Brignone, M., Diamand, F., Painchault, C., & Takyar, S.
Corresponding author
Brignone, Mélanie
ORCID
Venue
Current Medical Research and Opinion
Publisher
Informa UK Limited
Published
2016-01-16
Volume
32
Issue
2
Pages
351-366
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
DOI
10.1185/03007995.2015.1128404
OpenAlex
W2183172310
Cited by
30
References
83
Citations by year
2025: 2 · 2024: 2 · 2023: 6 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 3 · 2017: 5 · 2016: 1
FWCI
2.16
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Funders
Agency for Healthcare Research and Quality
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
Keywords
vortioxetine, major depressive disorder, antidepressant switching, inadequate response to antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, agomelatine, sertraline, venlafaxine, bupropion, remission rate, tolerability, indirect treatment comparison, evidence networks, monotherapy
MeSH terms
Vortioxetine, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Piperazines, Sulfides, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review